October 10, 2016
Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170
Nicox S.A. the international ophthalmic R&D company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for AC-170, its novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis.